CGEM (Cullinan Therapeutics) Debt-to-Equity : 0.00 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cullinan Therapeutics Debt-to-Equity?

Cullinan Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $1.30 Mil. Cullinan Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.85 Mil. Cullinan Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $590.33 Mil. Cullinan Therapeutics's debt to equity for the quarter that ended in Dec. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cullinan Therapeutics's Debt-to-Equity or its related term are showing as below:

During the past 7 years, the highest Debt-to-Equity Ratio of Cullinan Therapeutics was 0.01. The lowest was 0.00. And the median was 0.01.

CGEM's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Cullinan Therapeutics Debt-to-Equity Historical Data

The historical data trend for Cullinan Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Therapeutics Debt-to-Equity Chart

Cullinan Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.01

Cullinan Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.01	-	-	-

Competitive Comparison of Cullinan Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Cullinan Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cullinan Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cullinan Therapeutics's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Cullinan Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cullinan Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.302	+	0.849)	/	590.328
	=	0.00

Cullinan Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.302	+	0.849)	/	590.328
	=	0.00

Cullinan Therapeutics (NAS:CGEM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cullinan Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cullinan Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cullinan Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cullinan Therapeutics Inc (NAS:CGEM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Main Street, Suite 1350, Cambridge, MA, USA, 02142

Website

https://cullinantherapeutics.com

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Executives

Jacquelyn L Sumer	officer: Chief Legal Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Nadim Ahmed	director, officer: President and CEO	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeffrey Alan Jones	officer: Chief Medical Officer	ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Jennifer Michaelson	officer: See Remarks	C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Savill Corrine	officer: Acting Chief Business Officer	C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Jeffrey Trigilio	officer: Chief Financial Officer	C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142
David P. Ryan	director	C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Vision Scs F2	10 percent owner	74 GRAND RUE, LUXEMBURG N4 L-1660
F2 Bioscience I 2017 Ltd	10 percent owner	8, RUE SAINT-LEGER, GENEVA V8 CH 1205
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Anne-marie Martin	director	ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104